Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9UKV8: Variant p.His203Gln

Protein argonaute-2
Gene: AGO2
Feedback?
Variant information Variant position: help 203 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Histidine (H) to Glutamine (Q) at position 203 (H203Q, p.His203Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and polar. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In LESKRES; impairs shRNA-mediated silencing. Does not affect targeting to P-bodies. Increases binding to mRNA targets. Does not affect interaction with DICER1. Does not affect phosphorylation of the C-terminal serine cluster. Does not affect phosphorylation of Ser-387. Any additional useful information about the variant.


Sequence information Variant position: help 203 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 859 The length of the canonical sequence.
Location on the sequence: help TASEGCSNPLGGGREVWFGF H QSVRPSLWKMMLNIDVSATA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         TASE-GCSNPLGGGREVWFGFHQSV----RPSLWKMMLNIDVSATA

Mouse                         TASE-GCSNPLGGGREVWFGFHQSV----RPSLWKMMLNID

Rat                           TASE-GCSNPLGGGREVWFGFHQSV----RPSLWKMMLNID

Bovine                        TASE-GCSNPLGGGREVWFGFHQSV----RPSLWKMMLNID

Xenopus laevis                TASE-GCANPLGGGREVWFGFHQSV----RPSLWKMMLNID

Xenopus tropicalis            TASE-GCANPLGGGREVWFGFHQSV----RPSLWKMMLNID

Drosophila                    KMSDPNNRHELDDGYEALVGLYQAFMLGDRP-----FLNVD
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 859 Protein argonaute-2
Beta strand 196 – 207



Literature citations
Germline AGO2 mutations impair RNA interference and human neurological development.
Lessel D.; Zeitler D.M.; Reijnders M.R.F.; Kazantsev A.; Hassani Nia F.; Bartholomaeus A.; Martens V.; Bruckmann A.; Graus V.; McConkie-Rosell A.; McDonald M.; Lozic B.; Tan E.S.; Gerkes E.; Johannsen J.; Denecke J.; Telegrafi A.; Zonneveld-Huijssoon E.; Lemmink H.H.; Cham B.W.M.; Kovacevic T.; Ramsdell L.; Foss K.; Le Duc D.; Mitter D.; Syrbe S.; Merkenschlager A.; Sinnema M.; Panis B.; Lazier J.; Osmond M.; Hartley T.; Mortreux J.; Busa T.; Missirian C.; Prasun P.; Luettgen S.; Mannucci I.; Lessel I.; Schob C.; Kindler S.; Pappas J.; Rabin R.; Willemsen M.; Gardeitchik T.; Loehner K.; Rump P.; Dias K.R.; Evans C.A.; Andrews P.I.; Roscioli T.; Brunner H.G.; Chijiwa C.; Lewis M.E.S.; Jamra R.A.; Dyment D.A.; Boycott K.M.; Stegmann A.P.A.; Kubisch C.; Tan E.C.; Mirzaa G.M.; McWalter K.; Kleefstra T.; Pfundt R.; Ignatova Z.; Meister G.; Kreienkamp H.J.;
Nat. Commun. 11:5797-5797(2020)
Cited for: INVOLVEMENT IN LESKRES; VARIANTS LESKRES CYS-201; VAL-201; GLN-203; MET-357; THR-364; PRO-367; SER-573; ARG-733; TYR-751 AND ARG-760; CHARACTERIZATION OF VARIANTS LESKRES PRO-192; CYS-201; VAL-201; GLN-203; MET-357; THR-364; PRO-367; SER-573; ARG-733; TYR-751 AND ARG-760; SUBCELLULAR LOCATION; PHOSPHORYLATION AT SER-387; INTERACTION WITH DICER1;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.